← Leaderboards
Gregg C Fonarow
University Of California Los Angeles
$709,016
Attributed
$709,016
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $129.1K · FY2005–06$200K$150K$100K$50K$0
'05
'06
Funding mix
By agency
NIH$709,016 · 1
By mechanism
U01$709,016 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Frank Pajonk$12,966,735
- Caius Gabriel Radu$8,088,566
- Antoni Ribas$28,929,216
- Thomas Frederick Newton$18,826,829
- David A. Nathanson$10,691,258
Others in their field
Top investigators on “Beta Antiadrenergic Agent”
- Christopher M O'Connor · Duke University$18,508,673
- Michael A Kass · Washington University$9,081,282
- Bruce M Psaty · University Of Washington$5,047,845
- Kenneth Allen Holroyd · Ohio University Athens$2,665,090
- Jeffrey H Silverstein · Mount Sinai School Of Medicine Of Nyu$2,655,974
- Susan Heckbert · University Of Washington$2,562,214
Research focus
Beta Antiadrenergic AgentCardiovascular Disorder ChemotherapyCardiovascular Disorder EpidemiologyCardiovascular Disorder TherapyClinical ResearchClinical TrialsCombination TherapyCongestive Heart FailureCooperative StudyCost EffectivenessDigoxinExerciseHospital UtilizationHuman MortalityHuman SubjectHuman Therapy EvaluationLongitudinal Human StudyMedical ComplicationOutcomes ResearchPatient Oriented ResearchAce InhibitorsQuality Of Life
Grant awards (5)
ACTION - A CHF Trial Investigating Outcomes of Exercise$15,506
U01 · FY2006 · HL · contact PI
ACTION - A CHF Trial Investigating Outcomes of Exercise$129,116
U01 · FY2005 · HL
ACTION - A CHF Trial Investigating Outcomes of Exercise$76,507
U01 · FY2004 · HL
ACTION - A CHF Trial Investigating Outcomes of Exercise$311,235
U01 · FY2003 · HL
ACTION - A CHF Trial Investigating Outcomes of Exercise$176,652
U01 · FY2002 · HL